All In Biotech

Drug Trial Radar · NCT03488524

Open Label Extension Study of AMX0035 in Patients With ALS

Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Mar 29, 2018

Primary completion

Mar 1, 2021

Study completion Mar 1, 2021

Sponsor

Lead sponsor
Amylyx Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
Massachusetts General Hospital
First posted
Apr 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500, also known as CENTAUR).

Conditions

  • Amyotrophic Lateral Sclerosis
  • ALS

Interventions

  • AMX0035Drug

    Combination therapy of PB and TURSO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From the Baseline Visit in the OLE study through Week 132 or the Early Discontinuation (Final Safety) Visit for each participant (for up to approximately 132 weeks)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute-Dignity Health, St Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • University of California, Irvine

    Orange, California

  • California Pacific Medical Center

    San Francisco, California

  • University of Florida College of Medicine

    Gainesville, Florida

  • University of South Florida College of Medicine

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • University of Iowa, Carver College of Medicine

    Iowa City, Iowa

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Ochsner Neuroscience Institute

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan, Michigan Medicine

    Ann Arbor, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • Washington University Medical Center

    St Louis, Missouri

  • Neurology Associates, PC

    Lincoln, Nebraska

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina

  • The Ohio State University, Wexner Medical Center

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • The Penn Comprehensive Neuroscience Center

    Philadelphia, Pennsylvania

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Texas Neurology, PA

    Dallas, Texas

  • University of Texas Health Science Center, San Antonio

    San Antonio, Texas

  • Swedish Neuroscience Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.